Kopran Ltd
NSE:KOPRAN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
124.29
213.28
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Kopran Ltd
Revenue
Kopran Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Kopran Ltd
NSE:KOPRAN
|
Revenue
₹5.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Revenue
₹343.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
16%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Revenue
₹283.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Revenue
₹549.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Revenue
₹247.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Revenue
₹122.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
Kopran Ltd
Glance View
Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing and supplying international formulations (Finished Dosage Form) and active pharmaceutical ingredients (APIs). Its formulation business unit manufactures oral solid dosages and dry powder formulations for both penicillin and non-penicillin-based drugs. Its APIs business unit offers Sterile Cephalosporins and Carbapenems. The company also offers Macrolide, Antibacterial, Anticonvulsant, and Cardiovascular range of drugs. Its product offering includes antibiotics, cardiovascular, antidiabetic, gastrointestinal, pain management, drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, and anthelmintics. Its antibiotics brands include AMPIK 250 / 500, AMPIK SYRUP, and AMYN - 250 / 500. Its cardiovascular brands include CARDIOTEN - 25 / 50 / 100, CADITONE - 3.125 / 6.25 / 12.5 / 25 and KLODIP - 5 / 10.
See Also
What is Kopran Ltd's Revenue?
Revenue
5.9B
INR
Based on the financial report for Sep 30, 2025, Kopran Ltd's Revenue amounts to 5.9B INR.
What is Kopran Ltd's Revenue growth rate?
Revenue CAGR 5Y
7%
Over the last year, the Revenue growth was -7%. The average annual Revenue growth rates for Kopran Ltd have been 5% over the past three years , 7% over the past five years .